Procter & Gamble Health Limited has announced a dividend payment of ₹160 per share for its shareholders. This dividend declaration represents a significant return to investors and reflects the company's commitment to sharing profits with its equity holders.

Dividend Declaration Details

The company has officially declared the dividend at ₹160 per share, which will be distributed to eligible shareholders. This announcement demonstrates the company's financial stability and its policy of returning value to investors through regular dividend payments.

Shareholder Impact

The dividend declaration will provide direct financial benefits to shareholders who hold shares in Procter & Gamble Health Limited. Eligible shareholders will receive ₹160 for each share they own, subject to the company's record date and other applicable terms and conditions.

This dividend payment reflects the company's approach to capital allocation and its focus on delivering consistent returns to its investor base. The announcement is expected to be well-received by the shareholder community as it provides immediate value realization on their investment in the company.

Procter & Gamble Health Limited has announced its Q3FY26 unaudited financial results for the quarter ended December 31, 2025, showing strong revenue growth alongside margin pressures. The company reported revenue from operations of ₹3,739 million, marking a significant increase from ₹3,098 million in the corresponding quarter of the previous year, while profitability metrics faced headwinds during the reporting period.

Board Meeting and Regulatory Compliance

The Board of Directors approved the unaudited financial results at their meeting held on February 6, 2026, which commenced at 12:11 p.m. and concluded at 14:23 p.m. The results have been prepared in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and subjected to limited review by the company's statutory auditors.

Q3FY26 Financial Performance

The company's Q3FY26 results demonstrate robust top-line growth with contrasting profitability trends:

The company achieved strong revenue expansion while facing significant cost pressures that impacted overall profitability during the quarter.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Procter & Gamble Health demonstrated consistent growth momentum:

The nine-month performance shows stronger profitability growth compared to the quarterly results, indicating improved operational efficiency over the extended period.

Interim Dividend Declaration

The Board of Directors has declared an interim dividend for FY2025-26 of ₹160 per equity share, which includes a one-time special dividend of ₹50 per equity share. Key dividend details include:

The substantial dividend payout reflects the company's strong cash position and commitment to shareholder returns.

Operational Highlights

Procter & Gamble Health continues to focus on its pharmaceuticals segment as the single primary reportable business. The company has successfully transitioned its injection portfolio to contract manufacturing following the discontinuation of injection production at its Goa facility. The financial results reflect the company's strategic positioning in the healthcare sector with sustained revenue growth despite margin pressures in the current quarter.